Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Nov. 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of
View HTML
Toggle Summary Flexion Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
BURLINGTON, Mass. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 29 th Annual Credit Suisse Virtual Healthcare Conference . The
View HTML
Toggle Summary Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights
Company   reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $23 .7 million in third quarter 2020 BURLINGTON, Mass. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business
View HTML
Toggle Summary Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020
BURLINGTON, Mass. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, November 4, 2020 . The company hosted a conference call on October
View HTML
Toggle Summary Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 Million
Company to hold conference call today at 8:30 a.m. ET BURLINGTON, Mass. , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA (triamcinolone acetonide extended-release injectable suspension) net sales of $23.6 million for the quarter ended
View HTML
Toggle Summary Flexion Therapeutics to Present at the 2020 Cell & Gene Virtual Meeting on the Mesa
BURLINGTON, Mass. , Oct. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics , Inc. (Nasdaq:FLXN) announced today that Adam Muzikant, Ph.D., Senior Vice President, Business Development, will present at the annual 2020 Cell & Gene Virtual Meeting on the Mesa. Dr.
View HTML
Toggle Summary Flexion Therapeutics Announces Podium Presentation of FX301 Preclinical Data at Virtual ANESTHESIOLOGY 2020 Meeting
Previously presented preclinical findings show FX301 provided greater sustained, post-operative analgesic effect with no significant impairment in motor function compared to liposomal bupivacaine and placebo   BURLINGTON, Mass. , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc.
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Oct. 02, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of
View HTML
Toggle Summary Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference
BURLINGTON, Mass. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the H.C. Wainwright Virtual Healthcare Conference . The virtual
View HTML
Toggle Summary Flexion Therapeutics Announces Treatment of First Patient in Second Cohort of FX201 Phase 1 Dose-Escalation Trial
Five patients treated in first cohort of Phase 1 clinical trial evaluating the safety and tolerability of FX201; Drug Monitoring Committee (DMC) supported the initiation of the next dosing cohort BURLINGTON, Mass. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc.
View HTML